Iterum Therapeutics (NASDAQ:ITRM) Upgraded by Zacks Investment Research to Hold

Iterum Therapeutics} stock has undergone multiple analysts rating changes in the recent past.  Iterum Therapeutics Upgraded by Zacks Investment Research on 10/19/2021. In a note to investors, the firm issued a new rating of Hold. The analysts previously had rating of Sell.

View More Iterum Therapeutics (NASDAQ:ITRM) Upgraded by Zacks Investment Research to Hold

Earnings and Growth Analysis : Iterum Therapeutics (NASDAQ:ITRM)

Earnings results for Iterum Therapeutics , Analyst Opinion on Iterum Therapeutics , Earnings and Valuation of (NASDAQ:ITRM), Stock market Insights & financial analysis, Best stock to invest, Investment Idea,

View More Earnings and Growth Analysis : Iterum Therapeutics (NASDAQ:ITRM)

Earnings Report: Here’s what to expect from Iterum Therapeutics (NASDAQ:ITRM)

Earnings results for Iterum Therapeutics , Analyst Opinion on Iterum Therapeutics , Earnings and Valuation of (NASDAQ:ITRM), Stock market Insights & financial analysis, Best stock to invest, Investment Idea,

View More Earnings Report: Here’s what to expect from Iterum Therapeutics (NASDAQ:ITRM)

Analysts Estimate Report : What to Look Out for Iterum Therapeutics (NASDAQ:ITRM)

Earnings results for Iterum Therapeutics , Analyst Opinion on Iterum Therapeutics , Earnings and Valuation of (NASDAQ:ITRM), Stock market Insights & financial analysis, Best stock to invest, Investment Idea,

View More Analysts Estimate Report : What to Look Out for Iterum Therapeutics (NASDAQ:ITRM)

Should you short it before the Earnings result? : Iterum Therapeutics (NASDAQ:ITRM)

Earnings results for Iterum Therapeutics , Analyst Opinion on Iterum Therapeutics , Earnings and Valuation of (NASDAQ:ITRM), Stock market Insights & financial analysis, Best stock to invest, Investment Idea,

View More Should you short it before the Earnings result? : Iterum Therapeutics (NASDAQ:ITRM)